Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | BCL6 | P41182 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538542 | 0.79 | CCR1 (0.35) | L3MBTL1LMNASMN1; SMN2CCR1CCR5 | |
| SCHEMBL1702773 | 0.78 | LRRK2 (0.42) | L3MBTL1BCL6KMT2AMEN1ALDH1A1 | |
| SCHEMBL30751791 | 0.78 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL3559919 | 0.78 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL30072681 | 0.78 | LRRK2 (0.42) | L3MBTL1BCL6KMT2AMEN1ALDH1A1 | |
| SCHEMBL15691383 | 0.77 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL5805842 | 0.76 | ALDH1A1 (0.59) | L3MBTL1BCL6KMT2AMEN1ALDH1A1 | |
| SCHEMBL5802874 | 0.75 | KCNMA1 (0.40) | L3MBTL1BCL6KMT2AMEN1ALDH1A1 | |
| SCHEMBL17212756 | 0.75 | PRKACA (0.44) | L3MBTL1BCL6KMT2AMEN1ALDH1A1 | |
| SCHEMBL1721807 | 0.75 | PSMD14 (0.40) | KMT2AMEN1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859614-B | Method for preparing 2-chloro-3-cyano-4-methylpyridine | 盐城迪赛诺制药有限公司 | 2020-05-26 | — | — | CN | claimed |
| WO-2016118586-A1 | LOWCOST, HIGH YIELD SYNTHESIS OF NEVIRAPINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-07-28 | — | — | WO | claimed |
| EP-1064265-B8 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1326836-B1 | PROCESS FOR MAKING 3-AMINO-2-CHLORO-4-METHYLPYRIDINE | BOEHRINGER INGELHEIM CHEMICALS (US) | 2004-05-06 | — | — | EP | claimed |
| EP-1064265-B1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-04-14 | — | — | EP | claimed |
| EP-1326836-A1 | PROCESS FOR MAKING 3-AMINO-2-CHLORO-4-METHYLPYRIDINE | Boehringer Ingelheim Chemicals, Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| EP-1064265-A4 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMA (US) | 2003-02-12 | — | — | EP | claimed |
| US-6399781-B1 | A KEY INTERMEDIATE IN THE PRODUCTION OF NEVIRAPINE, STARTING BY REACTING ACETYLACETALDEHYDE DIMETHYL ACETAL WITH MALONONITRILE, IN THE PRESENCE OF AN AMMONIUM SALT CATALYST | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-06-04 | — | — | US | claimed |
| US-20020052507-A1 | Process for making 3-amino-2-chloro-4-methylpyridine | BOEHRINGER INGELHEIM CHEMICALS, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2002030901-A1 | PROCESS FOR MAKING 3-AMINO-2-CHLORO-4-METHYLPYRIDINE | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1064265-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-01-03 | — | — | EP | claimed |
| US-6111112-A | Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | claimed |
| WO-2000043365-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| EP-4633735-A1 | INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| CN-1312807-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1064265-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| US-6111112-A | Synthesis of 3-amino-2-chloro-4-methylpyridine from malononitrile and acetone | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000043365-A1 | SYNTHESIS OF 3-AMINO-2-CHLORO-4-METHYLPYRIDINE FROM MALONONITRILE AND ACETONE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052507-A1 | Process for making 3-amino-2-chloro-4-methylpyridine | MTAP, TPMT, AMPD2 | L3MBTL1 2376/4885BCL6 2533/4885KMT2A 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.